Prurigo Nodularis

Below is a list of our prurigo nodularis studies that are currently enrolling.


Topical Ruxolitinib Evaluation in Prurigo Nodularis

  • Population: Patients aged eighteen years and older
  • Study Condition: Prurigo Nodularis 
  • Study Design:  The purpose of this research study is to determine if an investigational cream, ruxolitinib 1.5% cream, is safe and effective to treat adults with prurigo nodularis. In this study, ruxolitinib cream will be compared to a “vehicle cream.”  The vehicle cream looks like the ruxolitinib cream but contains no ruxolitinib. This study can last up to 60 weeks, including up to 4 weeks for screening, up to 52 weeks for treatment, and 30 days for safety follow-up. Eligible participants will be randomized 1:1 to receive ruxolitinib 1.5% cream or vehicle cream for the first 12 weeks. For the following 40 weeks all participants will receive the ruxolitinib cream.
  • Compensation will be provided


Please contact Dr. Veronica Emmerich for more information regarding ongoing prurigo nodularis studies.


Phone: 843-876-0110